<DOC>
	<DOCNO>NCT00909740</DOCNO>
	<brief_summary>This Phase I , first-in-human , open-label , dose-escalation study MEGF0444A administer IV infusion patient advance solid tumor standard therapy either exist proven ineffective intolerable .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics MEGF0444A Administered Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically document , incurable , metastatic solid malignancy progress , fail respond regimen therapy know provide clinical benefit Inadequate hematologic organ function Anticancer therapy within 4 week prior initiation study treatment Adverse event prior anticancer therapy resolve Grade â‰¤ 1 , except alopecia Active infection autoimmune disease Pregnancy ( positive pregnancy test ) lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Solid Tumor</keyword>
	<keyword>Cancer</keyword>
</DOC>